Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

Fran Gregory, PharmD, MBA, VP of emerging therapies at Cardinal Health, talks about the importance of market access strategies in the cell and gene therapy space.

L7 Informatics’ Marcia Blackmoore on how structured data, digital workflows, and real-time orchestration are helping CDMOs deliver at scale without compromising quality.

Non-coding RNAs (ncRNAs), once considered the 'dark matter' of the genome, have now emerged as pivotal regulators in cancer ...

Joe DePinto from McKesson discussed the challenges facing cell and gene therapies, particularly around reimbursement, and ...

Emma Weston joined the clinical trial after running out of treatment options. For two years, she's been cancer free.

Adoptive cell therapy based on ex-vivo expanded tumor-infiltrating lymphocytes (TILs) has historically been most effective in the treatment of metastatic melanoma,1 with objective response rates of up ...

As the number of cell and gene therapies expands, it's increasingly important for long-term patient data, explained Fran ...

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy that is being studied for the treatment of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC) that is ...

Prime Medicine’s modular editing tech may lower off-target risk, but key data and funding milestones remain ahead. Find out ...

Suzuki, R. (2025) Evaluation of the Hair Growth-Promoting Effects of Combined Treatment with Hair Growth Stimulants. Health, ...